Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing
Antimicrobial Agents and Chemotherapy · 06.08.2025 · 69 (8)
DOI: 10.1128/aac.00356-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.08.2025. Verfasst von Nabila Ismail und 10 weiteren Autor:innen. Beteiligte Einrichtung: South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and He…. Hauptthemen laut MEDLINE: Diarylquinolines, Mycobacterium tuberculosis, Antitubercular Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIBIB NIH HHS, South African Medical Research Council.
Abstract (Originalsprache)
Phenotypic drug susceptibility testing (pDST) remains a widely used standard for determination of resistance for several drugs for the Mycobacterium tuberculosis complex. Next-generation sequencing technologies can identify heteroresistant populations at low frequencies, but little is known about the impact of heteroresistance on bedaquiline (BDQ) pDST results. We simulated heteroresistance using in vitro -generated MmpR5 mutants mixed with the progenitor strain at various percentages (1%–20%) and performed pDST using the BACTEC MGIT 960 platform (1 and 2 µg/mL BDQ concentrations) coupled with EpiCenter TB-eXtended individual drug Susceptibility Testing software. Targeted next-generation sequencing was used to quantify the mutant subpopulation in growth control tubes, which were expected to maintain the mutant: wild-type proportion throughout the assay. Growth units of these growth control tubes were also comparable with minor differences in time to positivity between ratio mixtures. Only when intermediate results were considered (i.e., when growth units in a drug-containing tube reach the threshold for resistance but only after a further week of incubation) could BDQ heteroresistance be detected at frequencies of approximately 1% by pDST at a critical concentration of 1 µg/mL. These intermediate results, commonly disregarded during routine testing, could lead to earlier detection of BDQ resistance and may avert adverse clinical outcomes. The ability of pDST, a widely available DST technique, to reveal the presence of BDQ-resistant subpopulations at the phenotypic testing stage could improve resistance determination and potentially reduce time to effective treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
- Centre for Tuberculosis, National Institute for Communicable Diseases, Johannesburg, South Africa.
- Translational Genomics Research Institute (TGen) North Clinical Laboratory, Flagstaff, Arizona, USA.
- University of California-San Francisco, San Francisco, California, USA.
ORCID-Profile: Nabila Ismail, Shaheed Vally Omar, Robin M Warren
Förderung
- NIAID NIH HHS
- NIBIB NIH HHS
- South African Medical Research Council
- NIH HHS
- FIC NIH HHS
- National Institutes of Health
Zitieren
APA
Ismail, N., Sirgel, F., Omar, S. V., Omar, S., de Kock, M., Spies, C., Folkerts, M., Theron, G., Engelthaler, D., Metcalfe, J., & Warren, R. M. (2025). Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing. Antimicrobial Agents and Chemotherapy, 69(8). https://doi.org/10.1128/aac.00356-25
Vancouver
Ismail N, Sirgel F, Omar SV, Omar S, de Kock M, Spies C, et al. Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing. Antimicrobial Agents and Chemotherapy. 2025;69(8). doi:10.1128/aac.00356-25
BibTeX
@article{Ismail2025,
author = {Ismail, Nabila and Sirgel, Frik and Omar, Shaheed Vally and Omar, Shatha and de Kock, Marianna and Spies, Claudia and Folkerts, Megan and Theron, Grant and Engelthaler, Dave and Metcalfe, John and Warren, Robin M},
title = {Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {8},
doi = {10.1128/aac.00356-25}
}
EUVIMED